Published: 10 April 2021

Committees

Comments on agenda items for the 68th meeting of the Medicines Classification Committee to be held on 26 April 2022

The Medicines Classification Committee and the Secretary wish to thank everyone for their valuable input and feedback.

A total of 22 submissions commenting on agenda items for the 68th meeting was received (PDF, 3.71MB, 46 pages). Some of the submissions commented on more than one agenda item. Two submissions and some parts of the comments and have been withheld from publication for reasons described under clause 2b of the Official Information Act 1982.

Agenda Item 5.3 (9.a) Nicotine

One comment was received about this agenda item

Agenda Item 6.1 Nitrofurantoin (modified release) – proposed change to prescription classification statement (MACROBID, Te Arai BioFarma Limited)

Five comments were received about this agenda item.

Agenda Item 6.2 Naloxone – proposed down-scheduling change to classification (New Zealand Drug Foundation)

Two comments were received about this agenda item.

Agenda Item 7.1 Levomefolate

Sixteen comments were received about this agenda item.

Agenda Item 8.1b Estetrol monohydrate

One comment was received about this agenda item.